Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease

• Angela Minnella,

  Roles Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Writing – original draft, Writing – review & editing

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  ⨯
• Kevin P. McCusker,

  Roles Conceptualization, Data curation, Formal analysis, Investigation

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  ⨯
• Akiko Amagata,

  Roles Investigation

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  ⨯
• Beatrice Trias,

  Roles Formal analysis, Methodology, Validation

  Affiliation PTC Therapeutics, Warren, New Jersey, United States of America

  ⨯
• Marla Weetall,

  Roles Conceptualization, Formal analysis, Writing – original draft

  Affiliation PTC Therapeutics, Warren, New Jersey, United States of America

  ⨯
• Joey C. Latham,

  Roles Conceptualization, Data curation, Formal analysis, Investigation

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  ⨯
• Sloane O’Neill,

  Roles Writing – original draft, Writing – review & editing

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  ⨯
• Richard K. Wyse,

  Roles Supervision

  Affiliation Cure Parkinson’s, London, England, United Kingdom

  ⨯
• Matthew B. Klein,

  Roles Supervision

  Affiliation PTC Therapeutics, Warren, New Jersey, United States of America

  ⨯
• Jeffrey K. Trimmer

  Roles Conceptualization, Formal analysis, Supervision, Writing – original draft

  * E-mail: jtrimmer@ptcbio.com

  Affiliation PTC Therapeutics, Mountain View, California, United States of America

  https://orcid.org/0009-0009-6467-3574

  ⨯